Wedmont Private Capital Raises Stake in Zoetis Inc. (NYSE:ZTS)

Wedmont Private Capital increased its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 18.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,053 shares of the company’s stock after purchasing an additional 321 shares during the period. Wedmont Private Capital’s holdings in Zoetis were worth $353,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. American National Bank lifted its holdings in Zoetis by 469.2% during the 2nd quarter. American National Bank now owns 148 shares of the company’s stock worth $25,000 after purchasing an additional 122 shares in the last quarter. Financial Management Professionals Inc. lifted its holdings in Zoetis by 117.4% during the 1st quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after purchasing an additional 81 shares in the last quarter. Mystic Asset Management Inc. purchased a new stake in Zoetis during the 4th quarter worth about $37,000. Finally, Worth Asset Management LLC purchased a new stake in Zoetis during the 1st quarter worth about $26,000. Hedge funds and other institutional investors own 91.05% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $157.19 on Tuesday. The stock has a market cap of $73.59 billion, a price-to-earnings ratio of 35.64, a P/E/G ratio of 2.74 and a beta of 0.77. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. Zoetis Inc. has a 1-year low of $154.18 and a 1-year high of $249.27. The stock’s 50-day moving average is $169.18 and its 200 day moving average is $174.39.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 earnings per share. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.01 EPS for the current fiscal year.

Insider Activity at Zoetis

In related news, CEO Kristin C. Peck sold 311 shares of the firm’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total transaction of $55,980.00. Following the transaction, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Kristin C. Peck sold 311 shares of the firm’s stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $180.00, for a total transaction of $55,980.00. Following the transaction, the chief executive officer now directly owns 39,743 shares in the company, valued at approximately $7,153,740. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,501 shares of company stock valued at $2,949,073. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. StockNews.com raised Zoetis from a “buy” rating to a “strong-buy” rating in a report on Friday, September 9th. Stifel Nicolaus lowered their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, June 24th. Piper Sandler initiated coverage on Zoetis in a report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. The Goldman Sachs Group lowered their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $224.00.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.